Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTx-1301 (dexmethylphenidate) in pediatric ADHD
NCT05286762Phase 3Completed
- Sponsor
- Cingulate Inc.
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of CTx-1301 in attention deficit hyperactivity disorder (ADHD), sponsored by Cingulate Inc.. Started Aug 2023; status: completed.
02
Drugs
CTx-1301
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05286762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286762.